**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 53169

**Manuscript Type:** META-ANALYSIS

**Role of *IL-17* gene polymorphisms in osteoarthritis: A meta-analysis based on observational studies**

Yang HY *et al*. Role of *IL-17* gene polymorphisms in osteoarthritis

Hao-Yu Yang, Yu-Zhou Liu, Xin-Die Zhou, Yong Huang, Nan-Wei Xu

**Hao-Yu Yang, Yu-Zhou Liu,** Department of Orthopedics, Wuxi 9th People’s Hospital affiliated to Soochow University, Wuxi 214000, Jiangsu Province, China

**Xin-Die Zhou, Yong Huang, Nan-Wei Xu,** Department of Orthopedics, The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, Changzhou 213003, Jiangsu Province, China

**Author contributions:** Yang HY and Liu YZ contributed equally to this work; Yang YH, Huang Y, and Xu NW designed the research; Yang YH, Liu YZ and Zhou XD performed the research; Yang HY and Liu YZ contributed new reagents/analytic tools; Zhou XD and Xu NW analyzed the data; and Yang YH, Liu YZ and Huang Y wrote the paper.

**Supported by** National Natural Science Foundation of China, No. 81702179; Major scientific and technological project of Changzhou municipal commission of health and family planning, No. ZD201809.

**Corresponding author:** **Yong Huang, MD, Doctor, Full Professor,** Department of Orthopedics, The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, No. 29 Xinglong Road, Tianning District, Changzhou 213003, Jiangsu Province, China. huangyong@njmu.edu.cn

**Received:** December 11, 2019

**Revised:** March 6, 2020

**Accepted:** April 24, 2020

**Published online:**

**Abstract**

BACKGROUND

Osteoarthritis (OA) is a chronic complex multifactorial joint disease, and a major degenerative form of arthritis. Existing studies on the association between polymorphisms of the *IL-17* gene and the risk of OA in different populations have yielded conflicting findings.

AIM

To investigate the association between polymorphisms of the *IL-17* gene and the risk of OA.

Methods

We conducted a meta-analysis by systematically searching databases, including PubMed, EMBASE, MEDLINE, Cochrane Library, and Google Scholar to evaluate this association by calculating pooled odds ratios with 95% confidence intervals. Moreover, subgroup analyses stratified by ethnicity and OA type were also conducted.

Results

In a total of 6 citations involving 8 studies (2131 cases and 2299 controls), 4 single nucleotide polymorphisms were identified. Of these 4 polymorphisms, 2 (rs2275913, rs763780) were common in five case-control studies. Together, the pooled results revealed that the A allele and genotype AA/GA of the rs2275913 polymorphism, and the C allele and genotype CC of the rs763780 polymorphism in the *IL-17* gene increased the risk of OA. Furthermore, stratification analyses by ethnicity and OA type showed that the rs2275913 polymorphism increased the risk of OA among Asians and in knee/hip OA, respectively. In addition, stratification analyses also revealed that the rs763780 polymorphism increased OA risk among both Asians and Caucasians in knee/hip OA.

Conclusion

The rs763780 polymorphism of the *IL-17F* gene increased the risk of OA, whereas the rs2275913 polymorphism of the *IL-17A* gene increased the risk of OA only among Asians. Due to the limitations of this study, these findings should be validated in future studies.

**Key words:** Interleukin-17; Polymorphism; Osteoarthritis; Meta-analysis; Odds ratio; Confidence interval

Yang HY, Liu YZ, Zhou XD, Huang Y, Xu NW. Role of *IL-17* gene polymorphisms in osteoarthritis: A meta-analysis based on observational studies. *World J Clin Cases* 2020; In press

**Core tip:** Osteoarthritis (OA) is the combined result of complex pathogenic factors, including mechanical, biochemical, environmental, endocrine, metabolic, and genetic factors, which account for nearly 50% of the risk of OA development. Although the pathogenesis and etiology of OA are not known, it is likely that interleukin-17 (IL-17) might play an important role in OA development. Existing studies on the association between polymorphisms of the *IL-17* gene and the risk of OA in different populations have yielded conflicting findings. We meta-analyzed relevant articles to pool available data and investigated whether *IL-17* gene polymorphisms were associated with OA susceptibility.

**INTRODUCTION**

Osteoarthritis (OA) is a common form of arthritis that can cause progressive loss of joint function[1]. OA is characterized by softening, splitting, and fragmentation of articular cartilage, which is usually accompanied by subchondral bone sclerosis, bone cysts, and bony outgrowths at the joint margins[2]. OA is the combined result of complex pathogenic factors, including mechanical, biochemical, environmental, endocrine, metabolic, and genetic factors, which account for nearly 50% of the risk of OA development[3-6]. Some previous genome-wide association studies[7,8] have suggested that polymorphisms in some genes may affect OA pathogenesis. Genetic markers, in combination with imaging (such as X-ray, magnetic resonance imaging and ultrasound[9,10]) and biochemical markers, have the potential to assist in identifying and diagnosing OA in the early stage[11].

One of the most important family of genes associated with OA is the inflammatory cytokines gene family[12]. Inflammatory cytokines [such as interleukin-1β (IL-1β), IL-6, tumor necrosis factor-α, matrix metalloprotein-13] and moderate physical activity together play a possible biological role in the development of OA[13,14]. IL-17 involves five confirmed receptors and six members (IL-17A-F)[15,16]. Recent evidence has shown that IL-17 was detectable in serum samples and synovial fluid from OA subjects, and a direct correlation between the IL-17 concentration and the severity of OA was observed[17,18]. IL-17 induces the release of chemokines by chondrocytes and synovial fibroblasts, which contributed to synovial infiltration and cartilage collapse in OA[19]. Although the pathogenesis and etiology of OA are not known, it is likely that IL-17 might play an important role in OA development.

To date, several studies[12,20-24] have explored the relationship between polymorphisms of the *IL-17* gene and OA susceptibility. The association between *IL-17* gene single nucleotide polymorphisms (SNPs) and OA susceptibility may provide novel research directions for OA studies[2]. However, the results of previous studies are inconclusive and conflicting due to clinical heterogeneity, different ethnic populations and small sample sizes. Meta-analysis is a statistical system for assembling results from different studies to produce a single approximate of the major effect with enhanced precision, especially when the results from single case-control studies are incomprehensive and conflicting. Therefore, in the present study we aimed to pool available data and investigated whether *IL-17* gene polymorphisms were associated with OA susceptibility.

**MATERIALS AND METHODS**

The current meta-analysis was performed by following the PRISMA statement[25].

***Search strategy***

We systematically conducted a literature search using the following electronic databases: PubMed, EMBASE, MEDLINE, Cochrane Library, and Google Scholar to identify epidemiological studies published up to September 2019 to retrieve genetic association studies on OA. The terms “Interleukin-17”, “IL-17”, “SNP”, “polymorphism”, “variant”, “osteoarthritis” and “OA” were used to identify all publications reporting *IL-17* gene polymorphisms and OA risk. No language or other restrictions were placed on the search. Eligible studies were retrieved and cautiously evaluated. Furthermore, the reference lists of all related citations were screened to identify any missing studies.

***Inclusion and exclusion criteria***

Articles were filtered by two independent reviewers (Yang HY and Liu YZ) to assess the appropriateness of the articles selected using a standardized protocol and data collection form. The inclusion criteria were as follows: (1) case-control studies on humans; (2) comparison between OA patients and controls; (3) studies evaluating the association between *IL-17* gene polymorphisms and OA susceptibility; and (4) studies with sufficient genetic frequency for extraction. The exclusion criteria were as follows: (1) studies with lack of information for data extraction; (2) non-human studies, abstracts only, comments, reviews, editorials or letters, mechanistic studies, and studies missing controls; and (3) duplicate or overlapping publications. All questionable publications were discussed and addressed by consensus.

***Data extraction and quality assessment***

From each eligible study, two reviewers (Yang HY and Liu YZ) independently extracted the following data: authors, publication date, country, ethnicity, sample size, type of OA, source of controls, allele, and genotype frequency distribution. In addition, the two reviewers independently assessed the methodological quality of the included studies according to the Newcastle-Ottawa Scale (NOS)[26]. NOS criteria were scored based on three aspects: (1) subject selection, 0-4; (2) comparability of subjects, 0-2; and (3) exposure, 0-3. The NOS score ranged from 0 (lowest) to 9 (highest). The Hardy-Weinberg equilibrium (HWE) in controls was tested with Pearson’s *χ2* test (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).

***Statistical analysis***

Quantitative meta-analysis was employed using STATA 11.0 software (STATA Corporation, College Station, TX, United States). To assess the association between *IL-17* gene polymorphisms and the risk of OA, pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Due to a lack of original data (sex and age), crude ORs were calculated, and five genetic models were included. *P* < 0.05 was considered statistically significant. Heterogeneity across studies was assessed by Q statistics with its *P*-value and I2 statistics[27,28]. If I2 > 50% and *P* < 0.10, a random effects model was used in the calculations; otherwise, a fixed effects model was applied. Subgroup analyses were carried based on ethnicity and type of OA. Moreover, the Begg’s test and Egger’s linear regression analysis were applied to prevent publication bias[29]. To evaluate the precision and consistency of the primary meta-analysis, sensitivity analysis was performed to verify the effects associated with any individual study. Furthermore, false-positive report probability (FPRP) was conducted to evaluate the significant findings and rule out any false associations due to multiple tests[30]. Generally, the FPRP value for a given association between *IL-17* gene polymorphisms and OA risk was calculated with different prior probability. An association with a FPRP value < 0.2 at a prior probability of 0.1 indicated a significant relationship.

**RESULTS**

***Characteristics of the included studies***

In this study, the literature search yielded 132 citations, among which 46 duplicates were removed. Then, 78 of the 86 remaining citations were excluded after reviewing the titles and abstracts. The remaining 8 citations were sent for full text review, which resulted in exclusion of 1 citation due to the lack of detailed genotype data and 1 non-SNP study. Finally, 6 citations (2131 cases and 2299 controls) involving 8 studies and 4 SNPs were included in this study. The year of publication ranged between 2014 and 2019. In four of the included citations[20-22,24], the association between *IL-17* gene polymorphisms in an Asian population were investigated, and in two included citations[12,23] focus was on the Caucasian population. In all 6 citations[12,20-24], the association between rs2275913/rs763780 polymorphisms of the *IL-17* gene and risk of OA were studied. Detailed characteristics of the included citations are shown in Tables 1 and 2. A flowchart of reviews, showing the detailed selection process, is illustrated in Figure 1. The NOS scores ranged from 6 to 7 stars.

***Association between*** ***rs******2275913 polymorphism and OA susceptibility***

General analysis showed that the polymorphism rs2275913 of the *IL-17A* gene increased OA risk [OR and 95%CI: 1.26 (1.08, 1.47) in A *vs* G; 1.25 (1.01, 1.55) in AA + GA *vs* GG; 1.53 (1.30, 1.81) in AA *vs* GA + GG; 1.71 (1.42, 2.06) in AA *vs* GG; and 1.15 (1.01, 1.32) in GA *vs* GG, Table 3 and Figure 2]. Stratification analysis by ethnicity showed that the rs2275913 polymorphism increased the risk of OA among Asians [OR and 95%CI: 1.40 (1.18, 1.67) in A *vs* G; 1.44 (1.13, 1.82) in AA + GA *vs* GG; 1.62 (1.34, 1.96) in AA *vs* GA + GG; 1.89 (1.52, 2.34) in AA *vs* GG; and 1.25 (1.06, 1.46) in GA *vs* GG, Table 3 and Figure 3); however, this was not observed in Caucasians. Subgroup analysis by OA type revealed that the rs2275913 polymorphism increased the risk of both knee and hip OA. A change in conclusion was not observed after eliminating a study[24] that did not meet the HWE.

Sensitivity analysis was used to determine the pooled ORs regarding the effects of this SNP on OA risk. Taken together, the results indicated that our data were stable and credible. Neither Egger’s nor Begg's tests revealed obvious publication bias for the rs2275913 polymorphism (Figure 4).

***Association between rs763780 polymorphisms and OA susceptibility***

Results of the pooled analysis on the association between *IL-17F* gene rs763780 polymorphism and OA risk are shown in Table 3 and Figure 5 [OR and 95%CI: 1.32 (1.06, 1.64) in C *vs* T; 1.32 (1.02, 1.72) in CC + TC *vs* TT; 2.08 (1.30, 3.32) in CC *vs* TC + TT; and 2.19 (1.37, 3.51) in CC *vs* TT]. Moreover, subgroup analysis by ethnicity indicated that rs763780 polymorphism increased OA risk among Caucasians in Allele/Dominant/Heterozygote models [OR and 95%CI: 1.75 (1.16, 2.66) in C *vs* T; 1.82 (1.11, 3.00) in CC + TC *vs* TT; and 1.84 (1.06, 3.17) in TC *vs* TT], whereas among Asians in Recessive/Homozygote models [OR and 95%CI: 2.17 (1.32, 3.59) in CC *vs* TC + TT; and 2.28 (1.37, 3.77) in CC *vs* TT]. Stratification analysis by OA type revealed that the rs763780 polymorphism increased the risk of both knee and hip OA. A change in conclusion was not observed after eliminating a study[24] that did not meet the HWE. Both sensitivity analysis and the publication bias test revealed that our data were stable and credible (data not shown).

***FPRP analysis result***

For all statistically significant results, the FPRP values are summarized in Table 4. For a prior probability of 0.1 and crude ORs, the FPRP analysis indicated that the significant association between IL-17A rs2275913 polymorphism and OA risk was significant for all subjects (allele: FPRP = 0.052, recessive: FPRP = 0.009, and homozygous comparison: FPRP = 0.009), Asians (allele: FPRP = 0.013, dominant: FPRP = 0.048, recessive: FPRP = 0.009, homozygous: FPRP = 0.009, and heterozygous comparison: FPRP = 0.103), and knee OA (recessive comparison: FPRP = 0.010). Similarly, the association of the *IL-17F* rs763780 polymorphism with OA risk also deserved attention in the overall population, especially among Caucasians and individuals with knee/hip OA. In our study, greater values were observed of FPRP > 0.2 for other positive findings between *IL-17* gene polymorphisms and OA risk, which may be attributed to the limited sample size. For future studies, additional validation will be needed using studies with a larger sample size.

**DISCUSSION**

Although the definite pathogenesis of OA remains unclear, genetic factors are considered to be strong determinants. IL-17 is a cytokine that is mainly synthesized by activated T cells, and its receptors are present in osteoblasts. IL-17 can enhance proinflammatory cytokines, including tumor necrosis factor-α, IL-1 and IL-6, that together play a key role in cartilage degradation and the inhibition of cartilage repair[31,32]. Furthermore, in patients with OA, IL-17 stimulates the release of vascular endothelial growth factor in synovial fibroblasts that was isolated from their joints[19]. Therefore, an increasing number of studies focused on the association between the *IL-17* gene polymorphisms and OA susceptibility.

Han *et al*[24] first examined the alleles and genotypes of *IL-17A* rs2275913 and *IL-17F* rs763780 in a Korean population, and found a significant association between rs2275913 and the susceptibility of knee OA. In addition, Vrgoc *et al*[23] did not observe an association between *IL-17A* rs2275913 and the risk of hip or knee OA in a Croatian population. The C allele of the *IL-17F* gene rs763780 polymorphism increased the risk of hip OA, but not of knee OA. The results of a study by Bafrani *et al*[12] indicated a significant association between rs2275913‐GA genotype and a decrease in the risk of knee OA. However, the rs763780‐TC genotype and rs763780‐C allele were related to an increased risk of knee OA. Zhang *et al*[20] suggested that the genotype AA frequency of *IL-17A* (rs2275913) was significantly different between knee OA patients and the control group in a Chinese Han population, but not in a Tibetan population. Furthermore, Bai *et al*[22] indicated that the *IL-17A* rs2275913 polymorphism had a significant impact on the risk of knee OA. Additionally, the rs763780 C allele was found to be related to a greatly increased risk of developing knee OA. Jiang *et al*[21] suggested a significant association between the increased risk of OA and *IL-17A* rs2275913, but not of *IL-17F* rs763780. The discrepancy in the above-mentioned studies may be due to the following: first, the inclusion criteria differed among studies. For example, Bai *et al*[22] enrolled other types of arthritis or joint diseases, such as inflammatory arthritis, which were excluded by other citations. Moreover, Jiang *et al*[21] used clinical symptoms and radiological evidence of joints, whereas in the Han *et al*[24] study, OA cases who had undergone total knee arthroplasty were enrolled. Second, the allele frequencies of the rs2275913/rs763780 polymorphism in the cases were diverse. Third, the affected joint sites differed. Fourth, the genetic background of OA may vary among races. Finally, the difference in sample sizes may also account for this discrepancy.

Due to the limited sample sizes, previous single studies may have been underpowered and thereby may have presented conﬂicting findings, especially given the diverse inheritance of the heterogeneous and complex OA etiology, different ethnicities, clinical heterogeneity, and other causes. Therefore, we conducted this meta-analysis.

Our data showed that the rs2275913 and rs763780 polymorphisms increased the risk of OA. Stratification analyses by ethnicity and OA type showed that the rs2275913 polymorphism increased the risk of OA among Asians as well as in knee/hip OA, respectively. Stratification analyses also revealed that the rs763780 polymorphism increased OA risk among both Asians and Caucasians, as well as in knee/hip OA. There may be several possible reasons for the different findings regarding the rs2275913 polymorphism between Asians and Caucasians. First, genetic heterogeneity for OA exists in different populations. Second, these discrepancies may be explained by clinical heterogeneity. Third, the sample sizes of the Caucasian populations were not large enough to support a definitive conclusion. Additionally, different OA types and varying clinical parameters of different populations may also be potential reasons for the inconclusive findings. Furthermore, different characteristics of the OA groups (such as age and sex) and disease severity may also be possible reasons for the discrepancies observed. Finally, varying environmental factors may also have contributed, because the interaction between genetic factors and environmental factors can eventually lead to the development of OA. Gao *et al*[33] and Lee *et al*[34] also conducted meta-analyses to study the association between *IL-17* gene rs2275913/rs763780 polymorphism and OA risk. We consider that our meta-analysis had several additional advantages. First, compared to the work by Lee *et al*[34], our meta-analysis of the rs3134069 polymorphism included one more case-controlled study[20]. Second, for rs2275913, Gao *et al*[33] regarded the G allele as a minor allele and then analyzed it in 5 genetic models. In fact, according to the dbSNP database, A allele is the true minor allele. Gao *et al*[33] misidentified the minor allele, which led to the wrong choice of genetic model. If the correct genetic model is selected, their results are consistent with our findings. This mistake was also found in the rs763780 polymorphism analysis. Third, FPRP was conducted in our meta-analysis to evaluate the significant findings and rule out any false associations due to multiple tests.

Our study has several limitations that should be considered. First, due to limited data, we were unable to conduct stratification analyses of other potential factors, such as age, sex, and age at OA onset. Second, our results were based on unadjusted estimates of confounding factors, which might have affected the final results. Third, although funnel plots and Egger’s tests revealed no publication bias, selection bias could not be fully prevented, because only studies published in the English language were searched. Fourth, we were unable to assess potential gene-gene or gene-environment interactions due to the lack of relevant data. Fifth, in future studies, clinical cases should be investigated to support the analytical results observed in this study. Sixth, we can only infer but cannot conclude that the *IL-17* gene rs2275913/rs763780 polymorphism is a susceptibility locus for other types of OA. Thus, further investigation into more types of OA is warranted. Finally, five genetic models of inheritance were used, thus, type I error may have arisen through lack of correction for multiple testing.

In conclusion, the present meta-analysis demonstrated that the rs763780 polymorphism of the *IL-17F* gene increased the risk of OA, whereas the rs2275913 polymorphism of the *IL-17A* gene only increased the risk of OA among Asians. Given the study limitations, further well-designed prospective studies with large sample sizes should be performed to validate these findings. In the future, it will become feasible to identify and diagnose OA in the early stage, as a result of genetic findings. Furthermore, the biological and functional relevance of these genetic findings is essential to help put the research into a clinical context to benefit people with OA.

**ARTICLE HIGHLIGHTS**

***Research background***

Osteoarthritis (OA) is the combined result of complex pathogenic factors, including mechanical, biochemical, environmental, endocrine, metabolic, and genetic factors, which account for nearly 50% of the risk of OA development. Although the pathogenesis and etiology of OA are not known, it is likely that interleukin-17 (IL-17) might play an important role in OA development.

***Research motivation***

To date, several studies have explored the relationship between polymorphisms of the *IL-17* gene and OA susceptibility. The association between *IL-17* gene single nucleotide polymorphisms and OA susceptibility may provide novel research directions for OA studies. However, the results of previous studies are inconclusive and conflicting due to clinical heterogeneity, different ethnic populations and small sample sizes.

***Research objectives***

We meta-analyzed relevant articles regarding the association between the polymorphisms of *IL-17* gene and OA susceptibility.

***Research methods***

We systematically conducted the literature search using the following electronic databases: PubMed, EMBASE, MEDLINE, Cochrane Library, and Google Scholar to identify epidemiological studies published up to September 2019 to retrieve genetic association studies on OA. Pooled odds ratios with 95% confidence intervals were calculated. Subgroup analyses were carried based on ethnicity and type of OA. Furthermore, false-positive report probability was conducted to evaluate the significant findings and rule out any false associations due to multiple tests.

***Research results***

In a total of 6 citations involving 8 studies (2131 cases and 2299 controls), 4 single nucleotide polymorphisms were identified. Of these 4 polymorphisms, 2 (rs2275913, rs763780) were common in five case-control studies. Together, the pooled results revealed that the A allele and genotype AA/GA of the rs2275913 polymorphism, and the C allele and genotype CC of the rs763780 polymorphism in the *IL-17* gene increased the risk of OA. Furthermore, stratification analyses by ethnicity and OA type showed that the rs2275913 polymorphism increased the risk of OA among Asians and in knee/hip OA, respectively. In addition, stratification analyses also revealed that the rs763780 polymorphism increased OA risk among both Asians and Caucasians in knee/hip OA.

***Research conclusions***

The rs763780 polymorphism of the *IL-17F* gene increased the risk of OA, whereas the rs2275913 polymorphism of the *IL-17A* gene increased the risk of OA only among Asians. Due to the limitations of this study, these findings should be validated in future studies.

**REFERENCES**

1 **Valdes AM**, Spector TD. Genetic epidemiology of hip and knee osteoarthritis. *Nat Rev Rheumatol* 2011; **7**: 23-32 [PMID: 21079645 DOI: 10.1038/nrrheum.2010.191]

2 **Valdes AM**, Spector TD. The contribution of genes to osteoarthritis. *Rheum Dis Clin North Am* 2008; **34**: 581-603 [PMID: 18687274 DOI: 10.1016/j.rdc.2008.04.008]

3 **Loughlin J**. The genetic epidemiology of human primary osteoarthritis: current status. *Expert Rev Mol Med* 2005; **7**: 1-12 [PMID: 15910695 DOI: 10.1017/S1462399405009257]

4 **Meulenbelt I**. Osteoarthritis year 2011 in review: genetics. *Osteoarthritis Cartilage* 2012; **20**: 218-222 [PMID: 22261407 DOI: 10.1016/j.joca.2012.01.007]

5 **Zou T**, Yang L, Lee AM, Tan X, Wong E, Bai HX. Can genetics explain the higher risk of worsening knee pain in offspring of people with total knee replacement for severe primary knee osteoarthritis? *Ann Rheum Dis* 2016; **75**: e45 [PMID: 26964145 DOI: 10.1136/annrheumdis-2016-209380]

6 **Reynard LN**. Analysis of genetics and DNA methylation in osteoarthritis: What have we learnt about the disease? *Semin Cell Dev Biol* 2017; **62**: 57-66 [PMID: 27130636 DOI: 10.1016/j.semcdb.2016.04.017]

7 **Pang H**, Luo F, Dai F, Wu XH, Xu JZ. Genome-wide association study for osteoarthritis. *Lancet* 2013; **381**: 372-273; discussion 373 [PMID: 23374473 DOI: 10.1016/S0140-6736(13)60167-1]

8 **arcOGEN Consortium.**; arcOGEN Collaborators, Zeggini E, Panoutsopoulou K, Southam L, Rayner NW, Day-Williams AG, Lopes MC, Boraska V, Esko T, Evangelou E, Hoffman A, Houwing-Duistermaat JJ, Ingvarsson T, Jonsdottir I, Jonnson H, Kerkhof HJ, Kloppenburg M, Bos SD, Mangino M, Metrustry S, Slagboom PE, Thorleifsson G, Raine EV, Ratnayake M, Ricketts M, Beazley C, Blackburn H, Bumpstead S, Elliott KS, Hunt SE, Potter SC, Shin SY, Yadav VK, Zhai G, Sherburn K, Dixon K, Arden E, Aslam N, Battley PK, Carluke I, Doherty S, Gordon A, Joseph J, Keen R, Koller NC, Mitchell S, O'Neill F, Paling E, Reed MR, Rivadeneira F, Swift D, Walker K, Watkins B, Wheeler M, Birrell F, Ioannidis JP, Meulenbelt I, Metspalu A, Rai A, Salter D, Stefansson K, Stykarsdottir U, Uitterlinden AG, van Meurs JB, Chapman K, Deloukas P, Ollier WE, Wallis GA, Arden N, Carr A, Doherty M, McCaskie A, Willkinson JM, Ralston SH, Valdes AM, Spector TD, Loughlin J. Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. *Lancet* 2012; **380**: 815-823 [PMID: 22763110 DOI: 10.1016/S0140-6736(12)60681-3]

9 **Razek AA**, El-Basyouni SR. Ultrasound of knee osteoarthritis: interobserver agreement and correlation with Western Ontario and McMaster Universities Osteoarthritis. *Clin Rheumatol* 2016; **35**: 997-1001 [PMID: 26089198 DOI: 10.1007/s10067-015-2990-2]

10 **Razek AA**, Fouda NS, Elmetwaley N, Elbogdady E. Sonography of the knee joint(). *J Ultrasound* 2009; **12**: 53-60 [PMID: 23397073 DOI: 10.1016/j.jus.2009.03.002]

11 **Warner S,** Valdes A. The Genetics of Osteoarthritis: A Review. *J Funct Morphol Kinesiol* 2016; **1**: 140-153 [DOI: 10.3390/jfmk1010140]

12 **Bafrani HH**, Ahmadi M, Jahantigh D, Karimian M. Association analysis of the common varieties of IL17A and IL17F genes with the risk of knee osteoarthritis. *J Cell Biochem* 2019; **120**: 18020-18030 [PMID: 31144366 DOI: 10.1002/jcb.29105]

13 **Castrogiovanni P**, Di Rosa M, Ravalli S, Castorina A, Guglielmino C, Imbesi R, Vecchio M, Drago F, Szychlinska MA, Musumeci G. Moderate Physical Activity as a Prevention Method for Knee Osteoarthritis and the Role of Synoviocytes as Biological Key. *Int J Mol Sci* 2019; **20** [PMID: 30691048 DOI: 10.3390/ijms20030511]

14 **Di Rosa M,** Castrogiovanni P, Musumeci G. The Synovium Theory: Can Exercise Prevent Knee Osteoarthritis? The Role of “Mechanokines”, A Possible Biological Key. *J Funct Morphol Kinesiol* 2019; **4**: 11 [DOI: 10.3390/jfmk4010011]

15 **Kawaguchi M**, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. *J Allergy Clin Immunol* 2004; **114**: 1265-1273; quiz 1274 [PMID: 15577820 DOI: 10.1016/j.jaci.2004.10.019]

16 **Kolls JK**, Lindén A. Interleukin-17 family members and inflammation. *Immunity* 2004; **21**: 467-476 [PMID: 15485625 DOI: 10.1016/j.immuni.2004.08.018]

17 **Neogi T**, Zhang Y. Epidemiology of osteoarthritis. *Rheum Dis Clin North Am* 2013; **39**: 1-19 [PMID: 23312408 DOI: 10.1016/j.rdc.2012.10.004]

18 **Agarwal S**, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. *J Rheumatol* 2008; **35**: 515-519 [PMID: 18203309]

19 **Honorati MC**, Bovara M, Cattini L, Piacentini A, Facchini A. Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. *Osteoarthritis Cartilage* 2002; **10**: 799-807 [PMID: 12359166 DOI: 10.1053/joca.2002.0829]

20 **Zhang PL**, Yang FM, Qiao ZZ, Liu J, Yang QY, Wang YJ, Qi M, Cui LN, Meng L, Li XP. [Association between interleukin-17A and 17F single nucleotide polymorphisms and knee osteoarthritis]. *Zhonghua Yi Xue Za Zhi* 2019; **99**: 1870-1874 [PMID: 31269582 DOI: 10.3760/cma.j.issn.0376-2491.2019.24.007]

21 **Jiang L**, Zhou X, Xiong Y, Bao J, Xu K, Wu L. Association between interleukin-17A/F single nucleotide polymorphisms and susceptibility to osteoarthritis in a Chinese population. *Medicine (Baltimore)* 2019; **98**: e14944 [PMID: 30896662 DOI: 10.1097/MD.0000000000014944]

22 **Bai Y**, Gao S, Liu Y, Jin S, Zhang H, Su K. Correlation between Interleukin-17 gene polymorphism and osteoarthritis susceptibility in Han Chinese population. *BMC Med Genet* 2019; **20**: 20 [PMID: 30658595 DOI: 10.1186/s12881-018-0736-0]

23 **Vrgoc G**, Vrbanec J, Eftedal RK, Dembic PL, Balen S, Dembic Z, Jotanovic Z. Interleukin-17 and Toll-like Receptor 10 genetic polymorphisms and susceptibility to large joint osteoarthritis. *J Orthop Res* 2018; **36**: 1684-1693 [PMID: 29194748 DOI: 10.1002/jor.23823]

24 **Han L**, Lee HS, Yoon JH, Choi WS, Park YG, Nam SW, Lee JY, Park WS. Association of IL-17A and IL-17F single nucleotide polymorphisms with susceptibility to osteoarthritis in a Korean population. *Gene* 2014; **533**: 119-122 [PMID: 24096234 DOI: 10.1016/j.gene.2013.09.113]

25 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010; **8**: 336-341 [PMID: 20171303 DOI: 10.1016/j.ijsu.2010.02.007]

26 **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]

27 **Melsen WG**, Bootsma MC, Rovers MM, Bonten MJ. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. *Clin Microbiol Infect* 2014; **20**: 123-129 [PMID: 24320992 DOI: 10.1111/1469-0691.12494]

28 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

29 **Peters JL**, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. *JAMA* 2006; **295**: 676-680 [PMID: 16467236 DOI: 10.1001/jama.295.6.676]

30 **He J**, Wang MY, Qiu LX, Zhu ML, Shi TY, Zhou XY, Sun MH, Yang YJ, Wang JC, Jin L, Wang YN, Li J, Yu HP, Wei QY. Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. *Mol Carcinog* 2013; **52 Suppl 1**: E70-E79 [PMID: 23423739 DOI: 10.1002/mc.22013]

31 **Tokuda H**, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O. Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. *J Cell Biochem* 2004; **91**: 1053-1061 [PMID: 15034939 DOI: 10.1002/jcb.20004]

32 **Katz Y**, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. *Arthritis Rheum* 2001; **44**: 2176-2184 [PMID: 11592383 DOI: 10.1002/1529-0131(200109)44:9<2176::aid-art371>3.0.co;2-4]

33 **Gao S**, Mao C, Cheng J, Deng Q, Sheng W. Association of IL-17A-197G/A and IL-17F-7488T/C polymorphisms and osteoarthritis susceptibility: A meta-analysis. *Int J Rheum Dis* 2020; **23**: 37-46 [PMID: 31670484 DOI: 10.1111/1756-185X.13737]

34 **Lee YH**, Song GG. Association between IL-17 gene polymorphisms and circulating IL-17 levels in osteoarthritis: a meta-analysis. *Z Rheumatol* 2019 [PMID: 31664512 DOI: 10.1007/s00393-019-00720-2]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**PRISMA 2009 Checklist statement:** The guidelines of the PRISMA 2009 Statement have been adopted.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** December11, 2019

**First decision:** January7, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** El-Razek AA, Musumeci G, Ünver B **S-Editor:** Webster JR Dou Y **L-Editor: E-Editor:**

**Figure Legends**

手机截图图社交软件的信息

描述已自动生成

**Figure 1 Flowchart of the literature search and selection for this study.**



**Figure 2 Forest plot shows odds ratios for the associations between rs2275913 polymorphism and osteoarthritis risk (AA + GA *vs* GG).**



**Figure 3 Stratification analysis by ethnicity shows odds ratio for the association between rs2275913 polymorphism and osteoarthritis risk (AA + GA *vs* GG).**

图片包含 游戏机

描述已自动生成

**Figure 4 Begg's tests between rs2275913 polymorphism and osteoarthritis (AA *vs* GA + GG).**



**Figure 5 Forest plot shows odds ratios for the associations between rs763780 polymorphism and osteoarthritis risk (CC *vs* TC + TT).**

**Table 1 Characteristics of included studies**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Yr** | **Nationality** | **Osteoarthritis type** | **Sample size (female/male)** | | **Age (mean)** | | **Study single nucleotide polymorphisms** | **Genotype method** | **Newcastle-Ottawa Scale** | | | **Hardy-Weinberg equilibrium** |
| **Case** | **Control** | **Case** | **Control** | **I** | **II** | **III** |
| Zhang *et al*[20] | 2019 | China | Knee | 122 (90/32) | 124 (88/36) | 66 | 66 | rs2275913 | PCR | 3 | 0 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs763780 | PCR | 3 | 0 | 3 | Yes |
| Zhang *et al*[20] | 2019 | China | Knee | 76 (52/24) | 68 (49/19) | 62 | 61 | rs2275913 | PCR | 3 | 0 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs763780 | PCR | 3 | 0 | 3 | Yes |
| Jiang *et al*[21] | 2019 | China | NA | 410 (271/139) | 507 (348/159) | 57.35 | 57.88 | rs2275913 | PCR-RFLP | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs763780 | PCR-RFLP | 3 | 1 | 3 | Yes |
| Bai *et al*[22] | 2019 | China | Knee | 594 (393/201) | 576 (402/174) | 59.5 | 58.3 | rs2275913 | PCR | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs763780 | PCR | 3 | 1 | 3 | Yes |
| Bafrani *et al*[12] | 2019 | Iran | Knee | 127 (69/58) | 127 (73/54) | 68.06 | 66.84 | rs2275913 | PCR-RFLP | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs763780 | PCR-RFLP | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs2397084 | PCR-RFLP | 3 | 1 | 3 | Yes |
| Vrgoc *et al*[23] | 2018 | Croatia | Hip | 260 (175/85) | 597 (152/445) | 67.82 | 42.64 | rs2275913 | TaqMan | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs763780 | TaqMan | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs1889570 | TaqMan | 3 | 1 | 3 | Yes |
| Vrgoc *et al*[23] | 2018 | Croatia | Knee | 240 (174/66) | 597 (152/445) | 69.74 | 42.64 | rs2275913 | TaqMan | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs763780 | TaqMan | 3 | 1 | 3 | Yes |
|  |  |  |  |  |  |  |  | rs1889570 | TaqMan | 3 | 1 | 3 | Yes |
| Han *et al*[24] | 2014 | SouthKorea | Knee | 302 (245/57) | 300 (136/164) | 60 | 51 | rs2275913 | PCR-SSCP | 3 | 0 | 3 | No |
|  |  |  |  |  |  |  |  | rs763780 | PCR-SSCP | 3 | 0 | 3 | No |

Newcastle-Ottawa Scale is available from [http://www.ohri.ca/programs/clinical epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical%20epidemiology/oxford.asp).

I: Selection; II: Comparability; III: Exposure; NA: Not available; PCR: Polymerase chain reaction; RFLP: Restriction fragment length polymorphism; SSCP: Single-strand conformation polymorphism.

**Table 2 Genotype distributions of *IL-17* gene polymorphisms in the included studies**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Source of control** | **Ethnicity** | **Allele** | | **Case** | | | **Control** | | | **Association with osteoarthritis** |
| **1** | **0** | **11** | **10** | **00** | **11** | **10** | **00** |
| **rs2275913** | | | | | | | | | | | |
| Zhang *et al*[20],2019 | HB | Asian | G | A | 42 | 53 | 27 | 49 | 63 | 12 | AA genotype/A allele increased OA risk |
| Zhang *et al*[20],2019 | HB | Asian |  |  | 23 | 32 | 21 | 26 | 28 | 14 | Not related |
| Jiang *et al*[21], 2019 | HB | Asian |  |  | 204 | 170 | 34 | 289 | 194 | 23 | AA genotype/A allele increased OA risk |
| Bai *et al*[22], 2019 | HB | Asian |  |  | 189 | 271 | 134 | 207 | 265 | 104 | AA genotype/A allele increased OA risk |
| Bafrani *et al*[12], 2019 | HB | Caucasians |  |  | 83 | 35 | 9 | 69 | 51 | 7 | GA genotype decreased OA risk |
| Vrgoc *et al*[23], 2018 | HB | Caucasians |  |  | 78 | 71 | 23 | 190 | 172 | 45 | Not related |
| Vrgoc *et al*[23], 2018 | HB | Caucasians |  |  | 76 | 85 | 25 | 190 | 172 | 45 | Not related |
| Han *et al*[24], 2014 | HB | Asian |  |  | 52 | 109 | 141 | 97 | 106 | 97 | GG genotype decreased OA risk |
| **rs763780** | |  |  |  |  |  |  |  |  |  |  |
| Zhang *et al*[20], 2019 | HB | Asian | T | C | 91 | 30 | 1 | 98 | 24 | 2 | Not related |
| Zhang *et al*[20], 2019 | HB | Asian |  |  | 59 | 16 | 1 | 54 | 13 | 1 | Not related |
| Jiang *et al*[21], 2019 | HB | Asian |  |  | 356 | 49 | 4 | 423 | 80 | 2 | Not related |
| Bai *et al*[22], 2019 | HB | Asian |  |  | 380 | 188 | 26 | 411 | 155 | 10 | CC/TC genotype/C allele increased OA risk |
| Bafrani *et al*[12], 2019 | HB | Caucasians |  |  | 98 | 26 | 3 | 112 | 13 | 2 | TC genotype/C allele increased OA risk |
| Vrgoc *et al*[23], 2018 | HB | Caucasians |  |  | 198 | 34 | 0 | 493 | 34 | 1 | C allele increased OA risk |
| Vrgoc *et al*[23], 2018 | HB | Caucasians |  |  | 195 | 14 | 1 | 493 | 34 | 1 | Not related |
| Han *et al*[24], 2014 | HB | Asian |  |  | 226 | 59 | 17 | 236 | 56 | 8 | Not related |
| **rs2397084** | |  |  |  |  |  |  |  |  |  |  |
| Bafrani *et al*[12], 2019 | HB | Caucasians | T | C | 111 | 16 | 0 | 109 | 18 | 0 | Not related |
| **rs1889570** | |  |  |  |  |  |  |  |  |  |  |
| Vrgoc *et al*[23], 2018 | HB | Caucasians | G | A | 57 | 129 | 58 | 49 | 91 | 46 | Not related |
| Vrgoc *et al*[23], 2018 | HB | Caucasians |  |  | 68 | 111 | 51 | 49 | 91 | 46 | Not related |

HB: Hospital-based; OA: Osteoarthritis.

**Table 3 Meta-analysis of the association between *IL-17* gene polymorphisms and osteoarthritis risk**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **SNP** | **Comparison** | **Category** | **Category** | **Studies** | **Odds ratio (95% confidence interval)** | ***P* value** | ***I2*** |
| rs2275913 | A *vs* G | Total (random model) |  | 8 | 1.26 (1.08, 1.47) | 0.003 | 61.6% |
| Allele model | Ethnicity | Asian | 5 | 1.40 (1.18, 1.67) | < 0.001 | 56.1% |
|  | Caucasian | 3 | 1.05 (0.84, 1.31) | 0.680 | 38.8% |
| OA type | Knee | 6 | 1.28 (1.04, 1.59) | 0.023 | 69.9% |
|  | Hip | 1 | 1.09 (0.83, 1.42) | 0.545 | - |
| AA + GA *vs* GG | Total (random model) |  | 8 | 1.25 (1.01, 1.55) | 0.039 | 61.0% |
| Dominant model | Ethnicity | Asian | 5 | 1.44 (1.13, 1.82) | 0.003 | 51.4% |
|  | Caucasian | 3 | 0.98 (0.68, 1.41) | 0.926 | 59.8% |
| OA type | Knee | 6 | 1.27 (0.93, 1.73) | 0.130 | 70.2% |
|  | Hip | 1 | 1.06 (0.74, 1.51) | 0.769 | - |
| AA *vs* GA + GG | Total (fixed model) |  | 8 | 1.53 (1.30, 1.81) | < 0.001 | 0.0% |
| Recessive model | Ethnicity | Asian | 5 | 1.62 (1.34, 1.96) | < 0.001 | 13.3% |
|  | Caucasian | 3 | 1.25 (0.88, 1.78) | 0.209 | 0.0% |
| OA type | Knee | 6 | 1.53 (1.27, 1.84) | < 0.001 | 0.0% |
|  | Hip | 1 | 1.24 (0.73, 2.13) | 0.430 | - |
| AA *vs* GG | Total (fixed model) |  | 8 | 1.71 (1.42, 2.06) | < 0.001 | 30.2% |
| Homozygote model | Ethnicity | Asian | 5 | 1.89 (1.52, 2.34) | < 0.001 | 40.8% |
|  | Caucasian | 3 | 1.28 (0.88, 1.86) | 0.192 | 0.0% |
| OA type | Knee | 6 | 1.74 (1.41, 2.15) | < 0.001 | 39.8% |
|  | Hip | 1 | 1.25 (0.71, 2.20) | 0.449 | - |
| GA *vs* GG | Total (fixed model) |  | 8 | 1.15 (1.01, 1.32) | 0.034 | 47.7% |
| Heterozygote model | Ethnicity | Asian | 5 | 1.25 (1.06, 1.46) | 0.007 | 23.7% |
|  | Caucasian | 3 | 0.98 (0.77, 1.24) | 0.846 | 63.1% |
| OA type | Knee | 6 | 1.15 (0.98, 1.36) | 0.090 | 60.3% |
|  | Hip | 1 | 1.01 (0.69, 1.47) | 0.977 | - |
| rs763780 | C *vs* T | Total (random model) |  | 8 | 1.32 (1.06,1.64) | 0.013 | 51.5% |
| Allele model | Ethnicity | Asian | 5 | 1.19 (0.95, 1.48) | 0.132 | 42.6% |
|  | Caucasian | 3 | 1.75 (1.16, 2.66) | 0.008 | 39.3% |
| OA type | Knee | 6 | 1.37 (1.17, 1.60) | < 0.001 | 0.0% |
|  | Hip | 1 | 2.24 (1.38, 3.63) | 0.001 | - |
| CC + TC *vs* TT | Total (random model) |  | 8 | 1.32 (1.02, 1.72) | 0.033 | 58.4% |
| Dominant model | Ethnicity | Asian | 5 | 1.15 (0.90, 1.48) | 0.274 | 44.0% |
|  | Caucasian | 3 | 1.82 (1.11, 3.00) | 0.018 | 51.9% |
| OA type | Knee | 6 | 1.35 (1.14, 1.61) | 0.001 | 0.0% |
|  | Hip | 1 | 2.42 (1.47, 3.99) | 0.001 | - |
| CC *vs* TC + TT | Total (fixed model) |  | 8 | 2.08 (1.30, 3.32) | 0.002 | 0.0% |
| Recessive model | Ethnicity | Asian | 5 | 2.17 (1.32, 3.59) | 0.002 | 0.0% |
|  | Caucasian | 3 | 1.48 (0.38, 5.67) | 0.570 | 0.0% |
| OA type | Knee | 6 | 2.10 (1.28, 3.45) | 0.003 | 0.0% |
|  | Hip | 1 | 0.76 (0.03, 3.32) | 0.864 | - |
| CC *vs* TT | Total (fixed model) |  | 8 | 2.19 (1.37, 3.51) | 0.001 | 0.0% |
| Homozygote model | Ethnicity | Asian | 5 | 2.28 (1.37, 3.77) | 0.001 | 0.0% |
|  | Caucasian | 3 | 1.62 (0.42, 6.23) | 0.481 | 0.0% |
| OA type | Knee | 6 | 2.23 (1.35, 3.67) | 0.002 | 0.0% |
|  | Hip | 1 | 0.83 (0.03, 20.43) | 0.909 | - |
| TC *vs* TT | Total (random model) |  | 8 | 1.29 (0.97, 1.71) | 0.078 | 62.6% |
| Heterozygote model | Ethnicity | Asian | 5 | 1.09 (0.85, 1.40) | 0.505 | 40.5% |
|  | Caucasian | 3 | 1.84 (1.06, 3.17) | 0.030 | 57.6% |
| OA type | Knee | 6 | 1.28 (1.07, 1.54) | 0.008 | 0.0% |
|  | Hip | 1 | 2.49 (1.51, 4.12) | < 0.001 | - |

OA: Osteoarthritis; SNP: Single nucleotide polymorphism.

**Table 4** **False-positive report probability values for associations between *IL-17* gene polymorphisms and risk of osteoarthritis**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Odds ratio (95%CI)** | ***P* value** | **Power** | **Prior probability** | | | | |
| **0.25** | **0.1** | **0.01** | **0.001** | **0.0001** |
| rs2275913 |  |  |  |  |  |  |  |  |
| A *vs* G |  |  |  |  |  |  |  |  |
| All | 1.26 (1.08, 1.47) | 0.003 | 0.488 | 0.018 | 0.052 | 0.378 | 0.860 | 0.984 |
| Asian | 1.40 (1.18, 1.67) | < 0.001 | 0.673 | 0.004 | 0.013 | 0.128 | 0.597 | 0.937 |
| Knee OA | 1.28 (1.04, 1.59) | 0.023 | 0.483 | 0.125 | 0.300 | 0.825 | 0.979 | 0.998 |
| AA + GA *vs* GG |  |  |  |  |  |  |  |  |
| All | 1.25 (1.01, 1.55) | 0.039 | 0.488 | 0.194 | 0.419 | 0.888 | 0.988 | 0.999 |
| Asian | 1.44 (1.13, 1.82) | 0.003 | 0.533 | 0.017 | 0.048 | 0.358 | 0.849 | 0.983 |
| AA *vs* GA + GG |  |  |  |  |  |  |  |  |
| All | 1.53 (1.30, 1.81) | < 0.001 | 0.952 | 0.003 | 0.009 | 0.094 | 0.512 | 0.913 |
| Asian | 1.62 (1.34, 1.96) | < 0.001 | 0.953 | 0.003 | 0.009 | 0.094 | 0.512 | 0.913 |
| Knee OA | 1.53 (1.27, 1.84) | < 0.001 | 0.890 | 0.003 | 0.010 | 0.100 | 0.529 | 0.918 |
| AA *vs* GG |  |  |  |  |  |  |  |  |
| All | 1.71 (1.42, 2.06) | < 0.001 | 0.991 | 0.003 | 0.009 | 0.091 | 0.502 | 0.910 |
| Asian | 1.89 (1.52, 2.34) | < 0.001 | 0.995 | 0.003 | 0.009 | 0.091 | 0.501 | 0.910 |
| GA *vs* GG |  |  |  |  |  |  |  |  |
| All | 1.15 (1.01, 1.32) | 0.034 | 0.447 | 0.186 | 0.406 | 0.883 | 0.987 | 0.999 |
| Asian | 1.25 (1.06, 1.46) | 0.007 | 0.548 | 0.037 | 0.103 | 0.559 | 0.927 | 0.992 |
| rs763780 |  |  |  |  |  |  |  |  |
| C *vs* T |  |  |  |  |  |  |  |  |
| All | 1.32 (1.06,1.64) | 0.013 | 0.509 | 0.071 | 0.187 | 0.717 | 0.962 | 0.996 |
| Caucasian | 1.75 (1.16, 2.66) | 0.008 | 0.487 | 0.047 | 0.129 | 0.619 | 0.943 | 0.994 |
| Knee OA | 1.37 (1.17, 1.60) | < 0.001 | 0.753 | 0.004 | 0.012 | 0.116 | 0.570 | 0.930 |
| Hip OA | 2.24 (1.38, 3.63) | 0.001 | 0.006 | 0.018 | 0.167 | 0.669 | 0.953 | 0.995 |
| CC + TC *vs* TT |  |  |  |  |  |  |  |  |
| All | 1.32 (1.02, 1.72) | 0.033 | 0.470 | 0.174 | 0.387 | 0.874 | 0.986 | 0.999 |
| Caucasian | 1.82 (1.11, 3.00) | 0.018 | 0.099 | 0.247 | 0.783 | 0.973 | 0.973 | 0.997 |
| Knee OA | 1.35 (1.14, 1.61) | 0.001 | 0.520 | 0.006 | 0.017 | 0.160 | 0.658 | 0.951 |
| Hip OA | 2.42 (1.47, 3.99) | 0.001 | 0.569 | 0.005 | 0.016 | 0.148 | 0.637 | 0.946 |
| CC *vs* TC + TT |  |  |  |  |  |  |  |  |
| All | 2.08 (1.30, 3.32) | 0.002 | 0.492 | 0.012 | 0.035 | 0.287 | 0.802 | 0.976 |
| Caucasian | 2.17 (1.32, 3.59) | 0.002 | 0.471 | 0.013 | 0.037 | 0.296 | 0.809 | 0.977 |
| Knee OA | 2.10 (1.28, 3.45) | 0.003 | 0.485 | 0.018 | 0.053 | 0.380 | 0.861 | 0.984 |
| CC *vs* TT |  |  |  |  |  |  |  |  |
| All | 2.19 (1.37, 3.51) | 0.001 | 0.487 | 0.006 | 0.018 | 0.169 | 0.672 | 0.954 |
| Caucasian | 2.28 (1.37, 3.77) | 0.001 | 0.469 | 0.006 | 0.019 | 0.174 | 0.681 | 0.955 |
| Knee OA | 2.23 (1.35, 3.67) | 0.002 | 0.526 | 0.011 | 0.033 | 0.274 | 0.792 | 0.974 |
| TC *vs* TT |  |  |  |  |  |  |  |  |
| Caucasian | 1.84 (1.06, 3.17) | 0.030 | 0.511 | 0.150 | 0.346 | 0.853 | 0.983 | 0.998 |
| Knee OA | 1.28 (1.07, 1.54) | 0.008 | 0.486 | 0.047 | 0.129 | 0.620 | 0.943 | 0.994 |
| Hip | 2.49 (1.51, 1.71) | < 0.001 |  |  |  |  |  |  |

OA: Osteoarthritis.